US Patent

US11911515 — Extended release compositions comprising pyridostigmine

Formulation · Assigned to Amneal Complex Products Research LLC · Expires 2038-06-18 · 12y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects extended release pyridostigmine dosage forms, including matrix tablets, gastroretentive tablets, and pellets, for controlled drug release.

USPTO Abstract

Extended release pyridostigmine dosage forms, suitable for maintaining stable plasma concentrations with reduced or minimized initial burst release/dose dumping of pyridostigmine, are provided. The dosage forms include matrix tablets, gastroretentive tablets, and pellets, the latter being suitable for dosing in capsules, tablets, and sachets, as well as for sprinkling on foodstuffs. The disclosure also provides methods for improving patient compliance by administering once-a-day extended release pyridostigmine bromide dosage forms that provide a superior controlled drug release.

Drugs covered by this patent

Patent Metadata

Patent number
US11911515
Jurisdiction
US
Classification
Formulation
Expires
2038-06-18
Drug substance claim
No
Drug product claim
Yes
Assignee
Amneal Complex Products Research LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.